Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion
- 92 Downloads
Compliance with ethical standards
All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. No financial disclosures. Both authors (D.C. and M.C.) were involved in design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript.
The authors have full control of the primary data and they agree to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review their data if requested.
Conflict of interest
All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.
- 8.Călugăru D, Călugăru M (2016) Intravitreal aflibercept for macula oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab and ranibizumab. Eye (Lond) 30:766Google Scholar